82 related articles for article (PubMed ID: 27126094)
41. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?
Thompson A; Keyes M; Pickles T; Palma D; Moravan V; Spadinger I; Lapointe V; Morris WJ
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):415-21. PubMed ID: 20133083
[TBL] [Abstract][Full Text] [Related]
42. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
Lee SH; Kim HJ; Kim WC
Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
[TBL] [Abstract][Full Text] [Related]
43. Hypophysectomy for prostate cancer: a revival of old knowledge?
Flitsch J; Bernreuther C; Hagel C; Lüdecke DK
J Neurosurg; 2008 Oct; 109(4):760-4. PubMed ID: 18826367
[TBL] [Abstract][Full Text] [Related]
44. Early PSA level decline is an independent predictor of biochemical and clinical control for salvage postprostatectomy radiotherapy.
Blanchard P; Bakkour M; De Crevoisier R; Levy A; Baumert H; Patard JJ; Wibault P; Fizazi K; Bossi A
Urol Oncol; 2015 Mar; 33(3):108.e15-20. PubMed ID: 25176583
[TBL] [Abstract][Full Text] [Related]
45. Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy.
Bostancic C; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath R; Lief J; Gutman SE
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1431-7. PubMed ID: 17544597
[TBL] [Abstract][Full Text] [Related]
46. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
47. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?
Morris LM; Izard MA; Wan WY
Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524
[TBL] [Abstract][Full Text] [Related]
48. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
49. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
[TBL] [Abstract][Full Text] [Related]
50. End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer.
Narang AK; Trieu J; Radwan N; Ram A; Robertson SP; He P; Gergis C; Griffith E; Singh H; DeWeese TA; Honig S; Annadanam A; Greco S; DeVille C; McNutt T; DeWeese TL; Song DY; Tran PT
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):203-209. PubMed ID: 28094250
[TBL] [Abstract][Full Text] [Related]
51. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer.
Morote J; Trilla E; Esquena S; Abascal JM; Reventos J
Int J Cancer; 2004 Mar; 108(6):877-81. PubMed ID: 14712491
[TBL] [Abstract][Full Text] [Related]
52. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD
J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907
[TBL] [Abstract][Full Text] [Related]
53. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
[TBL] [Abstract][Full Text] [Related]
54. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.
Pickles T;
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1355-9. PubMed ID: 16406391
[TBL] [Abstract][Full Text] [Related]
55. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
56. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
Chauvet B; Félix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F
J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443
[TBL] [Abstract][Full Text] [Related]
57. Prostate-specific antigen kinetics under androgen deprivation therapy and prostate cancer prognosis.
Zhang LM; Jiang HW; Tong SJ; Zhu HQ; Liu J; Ding Q
Urol Int; 2013; 91(1):38-48. PubMed ID: 23774685
[TBL] [Abstract][Full Text] [Related]
58. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
59. Personalization of Treatment Intensity for Intermediate-Risk Prostate Cancer.
Zumsteg ZS
Int J Radiat Oncol Biol Phys; 2022 Mar; 112(3):744-746. PubMed ID: 35101195
[No Abstract] [Full Text] [Related]
60. Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.
Fuerea A; Baciarello G; Patrikidou A; Albigès L; Massard C; Di Palma M; Escudier B; Fizazi K; Loriot Y
Eur J Cancer; 2016 Jul; 61():44-51. PubMed ID: 27151554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
